NEUP
Neuphoria Therapeutics IncKey Statistics
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company devoted to developing pioneering therapies for mental health disorders, utilizing psychedelic compounds and advanced drug delivery technologies. With a strong focus on translating cutting-edge research into effective treatments for significant unmet needs in the mental health sector, Neuphoria is establishing itself as a leader in this rapidly evolving industry. The company boasts a robust pipeline of preclinical candidates, making it an attractive investment opportunity for institutional investors seeking to capitalize on the next wave of biotech innovations. Neuphoria's commitment to delivering transformative therapeutic solutions positions it as a key player in redefining the future of mental health care.
Fundamentals
| Revenue (TTM) | $14.99M |
| Gross Profit (TTM) | $14.99M |
| EBITDA | $-1.20M |
| Operating Margin | -12.40% |
| Return on Equity | -26.10% |
| Return on Assets | -4.25% |
| Revenue/Share (TTM) | $5.76 |
| Book Value | $5.52 |
| Price-to-Book | 0.80 |
| Price-to-Sales (TTM) | 1.69 |
| EV/Revenue | 0.109 |
| EV/EBITDA | -0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.39M |
| Float | $4.17M |
| % Insiders | 7.72% |
| % Institutions | 49.76% |
Historical Volatility
Volatility is currently expanding